Journal article · 2025 · Open access

From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)

Sarah Sauchelli, Courtney Levy, Ari Gnanasakthy, Vaidehi Dave, Lynda C. Doward, Kristina A. Fitzgerald, Robyn T. Carson

Frontiers in Pharmacology, 16, 1536401 · Published 11 April 2025 · DOI 10.3389/fphar.2025.1536401

Open PDFView at the publisherCite this paper

In brief

“From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)” is a 2025 journal article by Sarah Sauchelli and 6 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 3 citations as of 22 November 2026, which puts it in the top 4% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.

Citations
3
Most cited in
2026 (3)
Field-weighted impact
1.53
References
23
Authors
7

Abstract

Introduction: Information about a medicine published in the Summary of Product Characteristics (SmPC) and the product's package leaflet by the European Medicines Agency (EMA) is key to communicate its value to prescribers and patients. The aim of this study was to examine the inclusion of statements related to patient-reported outcomes (PROs) in these documents to communicate patients' perspectives and experiences of new nononcology medicines. Methods: Nononcology therapeutic indications recommended for approval by the EMA between 2018-2022 were identified. The Public Assessment Report(s) (PAR), SmPC, and package leaflet published for each indication were examined. Information about the indication and characteristics relating to how the PROs were assessed in confirmatory studies was extracted. Results: Most nononcology therapeutic indications (n = 98/140, 70%) contained PRO trial data but less than 50% (n = 64/140, 46%) had PRO-related statements in the SmPC and/or package leaflet. Most statements described treatment benefit (n = 60/64, 94%). Statements were most likely to be included in the SmPC and/or package leaflet if supported by at least 1 randomized controlled trial (n = 52/71, 73%), the endpoint assessed patient-reported symptoms or symptom burden (n = 56/71, 79%), and/or the PRO(s) were assessed as a primary endpoint (n = 24/24, 100%). Discussion: Although trial data pertaining to PROs are reviewed when evaluating nononcology drugs, shortfalls persist in the inclusion of PROs when describing treatment benefit in critical documents used to inform treatment decision-making.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Sauchelli, S., Levy, C., Gnanasakthy, A., Dave, V., Doward, L. C., Fitzgerald, K. A., & Carson, R. T. (2025). From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022). Frontiers in Pharmacology, 16, 1536401. https://doi.org/10.3389/fphar.2025.1536401

MLA 9

Sauchelli, Sarah, et al. “From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022).” Frontiers in Pharmacology, vol. 16, 2025, p. 1536401. https://doi.org/10.3389/fphar.2025.1536401.

Chicago

Sauchelli, Sarah, Courtney Levy, Ari Gnanasakthy, Vaidehi Dave, Lynda C. Doward, Kristina A. Fitzgerald, and Robyn T. Carson. 2025. “From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022).” Frontiers in Pharmacology 16: 1536401. https://doi.org/10.3389/fphar.2025.1536401.

Harvard

Sauchelli, S. et al. (2025) ‘From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)’, Frontiers in Pharmacology, 16, p. 1536401. doi:10.3389/fphar.2025.1536401.

IEEE

S. Sauchelli et al., “From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022),” Frontiers in Pharmacology, vol. 16, p. 1536401, 2025, doi: 10.3389/fphar.2025.1536401.

BibTeX

@article{sauchelli2025from,
  title     = {{From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)}},
  author    = {Sauchelli, Sarah and Levy, Courtney and Gnanasakthy, Ari and Dave, Vaidehi and Doward, Lynda C. and Fitzgerald, Kristina A. and Carson, Robyn T.},
  journal   = {Frontiers in Pharmacology},
  year      = {2025},
  volume    = {16},
  pages     = {1536401},
  doi       = {10.3389/fphar.2025.1536401},
  url       = {https://doi.org/10.3389/fphar.2025.1536401}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • Summary of Product Characteristics
  • package leaflets
  • European Medicines Agency
  • drug approval
  • regulatory information
  • clinical decision-making
  • symptom burden

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Sauchelli, S., Levy, C., Gnanasakthy, A., Dave, V., Doward, L. C., Fitzgerald, K. A., & Carson, R. T. (2025). From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022). Frontiers in Pharmacology, 16, 1536401. https://doi.org/10.3389/fphar.2025.1536401

How many times has this paper been cited?

3 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Pharmacology: sign in and open the PDF from this page.

Who wrote this paper?

Sarah Sauchelli, Courtney Levy, Ari Gnanasakthy, Vaidehi Dave, Lynda C. Doward, Kristina A. Fitzgerald, Robyn T. Carson.

What is the DOI of this paper?

10.3389/fphar.2025.1536401, permanently at https://doi.org/10.3389/fphar.2025.1536401. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.